Core One In Talks With Multiple Companies To Supply Psilocybin
Core One In Talks With Multiple Companies To Supply Psilocybin
Core One Labs Inc. (OTCQB:CLABF) (CSE:COOL)(Frankfurt:LD6), (WKN:A3CSSU) announced that it is in discussions with several pharmaceutical laboratories and research organizations to supply them with active pharmaceutical ingredient psilocybin to meet their psychedelic research needs.
Core One Labs Inc(OTCQB: CLABF) (CSE: COOL) (法兰克福:LD6)，（WKN: A3CSSU）宣布它 正在与多个药物实验室和研究组织讨论向他们提供活性药物成分 psilocybin 以满足他们的迷幻研究需求。
Scientific interest in psilocybin has grown exponentially in recent years, with many high profile clinical trials showing enormous potential for the psychedelic compound in treating various mental health and neurological disorders, such as anxiety, depression, obsessive-compulsive disorder, various addictions, as well as Alzheimer's and Parkinson's diseases, to name a few. Promising results from many of these trials, though still in early stages and requiring further study, have given rise to rapid growth of a psychedelic industry and the emergence of many public and private entities engaged in research with psychedelics intended for medical use.
近年来，科学界对psilocybin的兴趣呈指数级增长，许多备受瞩目的临床试验表明，这种迷幻化合物在治疗各种心理健康和神经系统疾病方面具有巨大的潜力，例如焦虑、抑郁、强迫症、各种成瘾以及阿尔茨海默氏症和帕金森氏病等。其中许多试验的结果令人鼓舞，尽管仍处于初期阶段，需要进一步研究，但促成了迷幻行业的快速发展，并出现了许多公共和私人实体从事用于医疗用途的迷幻药的研究。
The company has the potential to produce its own psychedelic compounds at a Good Manufacturing Practices facility, while, in collaboration with its partners, also manufactures and could supply its quality and cost-effective products to licensed clients in Canada.
该公司有可能在Good Manufacturing Practions工厂生产自己的迷幻化合物，同时还与其合作伙伴合作，生产高质量且具有成本效益的产品，并可能向加拿大的持牌客户提供其优质且具有成本效益的产品。
By streamlining a psychedelic supply chain and structuring itself as a vertically integrated business, Core One could control the production process of its products and develop an uninterrupted revenue stream. Management regards a robust and reliable supply chain as a key component in establishing its business clientele and capturing a large share of the medicinal and clinical psychedelics' market.
通过精简迷幻的供应链并将自己构建为垂直整合的业务，Core One可以控制其产品的生产过程并开发不间断的收入来源。管理层认为，强大而可靠的供应链是建立业务客户群和占据药物和临床迷幻药市场很大份额的关键组成部分。
"Engaging in talks with multiple companies to supply them with psychedelic compounds demonstrates how far the company has come since initial research and development stages to where it is now. Embarking on the sales aspect of our corporate strategy keeps us ahead of the pack when it comes to being a leading supplier of medicinal psychedelics. We believe that our ability to continue to execute on our goals demonstrates to shareholders and other pharmaceutical companies why Core One is positioned to disrupt the medical industry when it comes to mental health and addiction treatments," stated Joel Shacker, Core One Labs CEO.
“与多家公司进行谈判，为他们提供迷幻化合物，这表明该公司自最初的研发阶段以来已经走了多远。在成为药用迷幻药的领先供应商方面，我们开始进入公司战略的销售方面使我们处于领先地位。我们相信，我们继续实现目标的能力向股东和其他制药公司表明，为什么Core One有能力在心理健康和成瘾治疗方面颠覆医疗行业，” 他说 Joel Shacker，Core One Labs 首席执行官
Photo: Benzinga edit with photos by geralt, sergeitokmakov on Pixabay
照片：Benzinga 在 Pixabay 上用 geralt、sergeitokmakov 的照片进行编辑
Related News
相关新闻
Core One's Awakened Lays The Groundwork For The Large-Scale Production Of Psychedelic Compounds With Synthetic Production Of Psilocin
Core One's Awakened 为大规模生产迷幻化合物和合成生产赛洛辛奠定了基础